Z Gastroenterol 2017; 55(08): e57-e299
DOI: 10.1055/s-0037-1605033
Kurzvorträge
Leber und Galle
Hepatitis C – eine geheilte Erkrankung?: Donnerstag, 14 September 2017, 15:35 – 17:03, St. Petersburg/Forschungsforum 1
Georg Thieme Verlag KG Stuttgart · New York

High SVR12 rates with combination of NS5A- and NS5B- inhibitors for 24 weeks in liver transplanted patients

C Rupp
1   Medizinische Universitätsklinik Heidelberg, Medizinische Klinik IV, Heidelberg, Deutschland
,
T Hippchen
1   Medizinische Universitätsklinik Heidelberg, Medizinische Klinik IV, Heidelberg, Deutschland
,
P Sauer
2   Universitätsklinikum Heidelberg, Interdisziplinäres Endoskopiezentrum (IEZ), Heidelberg, Deutschland
,
J Pfeiffenberger
1   Medizinische Universitätsklinik Heidelberg, Medizinische Klinik IV, Heidelberg, Deutschland
,
W Stremmel
1   Medizinische Universitätsklinik Heidelberg, Medizinische Klinik IV, Heidelberg, Deutschland
,
P Schemmer
3   Universitätsklinikum Heidelberg, Klinik für Allgemein-, Viszeral- & Transplantationschirurgie, Heidelberg, Deutschland
,
DN Gotthardt
1   Medizinische Universitätsklinik Heidelberg, Medizinische Klinik IV, Heidelberg, Deutschland
,
A Mehrabi
3   Universitätsklinikum Heidelberg, Klinik für Allgemein-, Viszeral- & Transplantationschirurgie, Heidelberg, Deutschland
,
KH Weiss
1   Medizinische Universitätsklinik Heidelberg, Medizinische Klinik IV, Heidelberg, Deutschland
› Author Affiliations
Further Information

Publication History

Publication Date:
02 August 2017 (online)

Also available at
 

Introduction:

HCV recurrence after liver transplantation markedly impacts graft and patient survival. DAA therapy provides improved SVR12 rates in former difficult to treat patients, however experience in liver transplanted patients with HCV reinfection still is limited. In the context of organ shortage efficient HCV therapies are essential to prevent transplant loss and preserve organ function.

Aims:

Retrospective comparison of safety and efficiency of different anti-HCV treatment regimen in liver transplanted patients.

Methods:

Between January 2014 and October 2016 thirty nine patients with HCV reinfection after liver transplantation were treated with different SOF-based regimen. Thirteen patients were treated with SOF+INF ± RBV. Ten patients were treated with SOF+DAC ± RBV, eighteen patients were treated with fixed dose combination of SOF+LDV ± RBV and one patient was treated with SOF+SIM+RBV. Three patients were re-treated after relapse. Treatment duration was 12 – 24 weeks.

Results:

SVR12 rates were 10/13 (76.9%) in patients treated with SOF+INF ± RBV. All three patients with relapse were treated with fixed dose combination of SOF+LDV+RBV. 100% SVR12 were achieved in patients treated with SOF+DAC+RBV or SOF+LDV+RBV for 12 – 24 weeks. SVR12 rates after combination of NS5A- and NS5B- inhibitors for 24 weeks were significantly higher compared to all other therapy regimen (p = 0.016). Liver function was stable or improved in the majority of patients during treatment. All antiviral therapies were save and well tolerated without need of discontinuation of treatment or dose adjustment of immunosuppression.

Conclusion:

In our cohort we achieved high rates of SVR12 in liver transplanted patients after a 24 week course of treatment with SOF-based regimen. Especially combination of NS5A- and NS5B- inhibitors for 24 weeks seems to be successful in these difficult to treat population. As organ function seems to improve during therapy efficient cure of HCV is an important factor for organ preservation.